SFM
ALNY icon

Sphera Funds Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sphera Funds Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-600
Closed -$3.33M – 109
2016
Q2 		$3.33M Buy
+600
New +$37.8K 0.86% 35

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sphera Funds Management's ALNY Position: Q2 2026 in Review

Sphera Funds Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 10,800 shares worth $3.25M. The stake represents 0.42% of the portfolio and ranks #77 among its holdings. This is a return to the name: Sphera Funds Management previously reported a position in ALNY as recently as Q3 2024.

Sphera Funds Management first reported a position in ALNY in Q2 2015 and has held it in 13 quarters since. The position peaked at $19.2M in Q2 2018. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sphera Funds Management held 10,800 shares of Alnylam Pharmaceuticals worth $3.25M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Sphera Funds Management position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.42% of Sphera Funds Management's portfolio in Q2 2026, its #77 holding.
  • Sphera Funds Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 13 quarters since.
  • Sphera Funds Management's Alnylam Pharmaceuticals position peaked at $19.2M in Q2 2018.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.